Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5
Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to $5.
Read original at benzingaStocks · News reference
ADC Therapeutics Q2 Adj. EPS $(0.11) Beats $(0.21) Estimate, Sales $19.248M Miss $19.376M Estimate
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 56 percent increase over losses of $(0.25) per share from the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 11:33 AM
- Checked
- Aug 13, 2026, 11:33 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
ADC Therapeutics shares are trading lower after the company reported mixed Q2 financial results.
Read original at benzinga8-K filing — ADC Therapeutics SA (ADCT)
Filed: 2026-08-13 AccNo: 0000950103-26-012287 Size: 33 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarADC Therapeutics Q2 2026 Earnings Call Transcript
On Thursday, ADC Therapeutics (NYSE:ADCT) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial
Read original at benzinga